DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Thursday, April 30, 2015

VANCOUVER, British Columbia and MENLO PARK, Calif., April 30, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

The Company's clinical data from its Phase I/II study of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), entitled, "Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma," (abstract no. 2023) will be presented at ASCO during the Central Nervous System Tumors poster session on Monday, June 1, 2015 being held from 1:15 p.m. - 4:45 p.m. CDT.

A second abstract, entitled, "Activity of Dianhydrogalactitol Alone or with Platinum Drugs Against Non-small Cell Lung Cancer Cell Lines," (abstract no. e19145) will be published online at and

About VAL-083 

VAL-083 is a "first-in-class", small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.

As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).

DelMar is currently studying multi-center VAL-083 in a Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA).  Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. ( Identifier NCT01478178).

About DelMar Pharmaceuticals, Inc. 

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit; or contact DelMar Pharmaceuticals Investor Relations:  / (604) 629-5989 follow us on Twitter @DelMarPharma or  Investor Relations Counsel:  Amato & Partners LLC.

Safe Harbor Statement 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.


To view the original version on PR Newswire, visit:

SOURCE DelMar Pharmaceuticals, Inc.